Recent Updates
Recently added Catalysts

LTG-321

Phase 1

Undisclosed | Small molecule | Other |Latigo Biotherapeutics, Inc.|Trials Updated: Jun 29, 2026

LTG-321 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Aug 2025

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment112

FDA Designations

No designations recorded

LTG-321 clinical trials

LTG-321 · 1 trial · 1 indication

Phase 1 1
NCT07110610Phase 1 Single and Multiple Ascending Dose of LTG-321 in Healthy ParticipantsHealthy Participants
COMPLETED112 Analytics
PHASE1COMPLETED
Phase 1 Single and Multiple Ascending Dose of LTG-321 in Healthy Participants
Healthy Participants
NCT07110610112
Unlock trial analytics

Study Endpoints

Primary Endpoints

To evaluate the Incidence, severity, seriousness, and causality of treatment-emergent adverse events (TEAEs) of single and multiple ascending oral doses of LTG-321 in healthy participants
Up to 14 days of dosing

Incidence, severity, seriousness, and causality of treatment-emergent adverse events (TEAEs)

To evaluate the Pain Detection and Tolerance Threshold during Cold Pressor Test of LTG-321 in healthy male participants.
Up to 5 days of dosing

Change from baseline at various individual time points and at various intervals for time to reach pain detection threshold (PDT) and time to reach pain tolerance threshold (PTT), for each dose of LTG-321 vs. placebo.

Effect of Food on Pharmacokinetics of LTG-321
Up to approximately 48 hours post-dose in each treatment period

Assessment of the effect of a high-fat meal on systemic exposure of LTG-321 following a single oral dose administered under fed and fasted conditions.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
LTG-321EXPERIMENTALreceives active investigational drug
PlaceboPLACEBO_COMPARATORreceives placebo comparator

Interventions

NameTypeDescription
LTG-321DRUGactive investigational drug
PlaceboOTHERPlacebo-to-match LTG-321
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Male and female participants aged 18 to 55 years, inclusive, at the time of signing the informed consent. * Overtly healthy with no clinically relevant abnormalities based on the medical history, physical examinations, clinical laboratory evaluations, and 12-lead ECG that, in ...

Countries:New Zealand
Unlock Eligibility Criteria

Explore more on BiopharmaWatch

Latigo Biotherapeutics, Inc. (LTGO)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with LCompanies A to ZEvery biotech and pharma company we track